

8 August 2008

Chem-Bio News

1. LAWMAKERS SEEK ANTHRAX ANSWERS: *"Sen. Charles Grassley, an Iowa Republican, sent a letter to FBI Director Robert Mueller on Thursday saying "important questions" remain "about the FBI's seven-year investigation, the basis for its conclusion that Dr. Bruce Ivins conducted the attacks alone, and the events leading to his suicide."*

2. DOR BIOPHARMA ANNOUNCES INITIATION OF SECOND HUMAN CLINICAL TRIAL FOR RIVAX (TM), ITS RICIN TOXIN VACCINE: *"This new trial is intended to evaluate the safety and immunogenicity of an improved formulation of the vaccine containing an adjuvant that is expected to result in long lasting and high levels of protective antibodies."*

3. FUTURE DECONTAMINANT FOR THE DECONTAMINATION FAMILY OF SYSTEMS (DFOS) PROGRAM OFFICE: *"The DoD Joint Project Manager for Decontamination (JPM-Decon) is conducting a market survey to identify chemical and biological decontaminants that meet the U.S. Army Center for Health Promotion and Preventive Medicine (USACHPPM) civilian related chemical warfare agent exposure levels for chemical and biological defense."*

4. AMTRAK ORDERS ADDITIONAL PORTABLE SABRE 4000 ADVANCED DETECTION SYSTEMS: *"However, it is believed that Amtrak will continue to use only the explosives detection capabilities."*

Chem-Demil News

1. MILESTONES IN U.S. CHEMICAL WEAPONS STORAGE AND DESTRUCTION: *This US Army Chemical Materials Agency factsheet provides an overview of the US CW storage and destruction programs after 1969.*

2. MISSION AREA OVERVIEW: PROJECT MANAGER – CHEMICAL STOCKPILE ELIMINATION: *This US Army Chemical Materials Agency factsheet provides an overview of the chemical stockpile elimination program.*

CB Daily Report

Chem-Bio News

LAWMAKERS SEEK ANTHRAX ANSWERS

By Gary Fields and Evan Perez
The Wall Street Journal
August 8, 2008

"The Federal Bureau of Investigation says the evidence released Wednesday shows Dr. Ivins was the sole person responsible for the 2001 mailings that killed five people and sickened 17.

Some on Capitol Hill aren't so sure, and lawmakers have begun submitting follow-up questions to the bureau, seeking more information that could be examined later at hearings."

"Sen. Charles Grassley, an Iowa Republican, sent a letter to FBI Director Robert Mueller on Thursday saying "important questions" remain "about the FBI's seven-year investigation, the basis for its conclusion that Dr. Bruce Ivins conducted the attacks alone, and the events leading to his suicide." Sen. Grassley listed 18 questions, including when the bureau determined the anthrax came from Dr. Ivins's flask and when it determined its original chief suspect, former Fort Detrick scientist Steven Hatfill, couldn't have been the person responsible."

Sen. Grassley is calling for the Judiciary Committee to hold hearings. "There just hasn't been any willingness

to talk about it, and I think an attack on Congress ought to have more of an explanation," Sen. Grassley said. Some of the anthrax letters were delivered to Senate offices.

When asked if he thought Dr. Ivins was the anthrax mailer, Sen. Grassley said: "I hope so, so it comes to an end. But I'm not satisfied with what I've heard thus far."

The full article can be found at: http://online.wsj.com/article/SB121815668706822713.html?mod=googlenews_wsj

[Return to Top](#)

DOR BIOPHARMA ANNOUNCES INITIATION OF SECOND HUMAN CLINICAL TRIAL FOR RIVAX(TM), ITS RICIN TOXIN VACCINE

MarketWatch

August 7, 2008

"This new trial is intended to evaluate the safety and immunogenicity of an improved formulation of the vaccine containing an adjuvant that is expected to result in long lasting and high levels of protective antibodies. The new trial is being conducted as part of a program funded by a grant from the Orphan Products Division of the FDA ("Food and Drug Administration"). Dr. Ellen Vitetta, Director of the University of Texas Southwestern Medical Center's Cancer Immunobiology Center, is the Principal Investigator of the study.

DOR is presently conducting manufacturing and characterization of the new RiVax(TM) formulation according to the FDA's current good manufacturing practices ("cGMPs"), anticipating that it will match requirements for stockpiled vaccines predicted from current stability results and pre-clinical efficacy results in animals. RiVax (TM) has already been evaluated in a Phase I clinical trial to test the safety and immunogenicity of the subunit lacking an adjuvant. Those results demonstrated that the adjuvant-free RiVax(TM) was well tolerated and induced antibodies in humans that neutralized ricin toxin in tissue culture and in mice."

The full article can be found at: <http://www.marketwatch.com/news/story/dor-biopharma-announces-initiation-second/story.aspx?guid=%7BFA9FBB62-45BC-4B24-995A-D576E475B7FA%7D&dist=hppr>

[Return to Top](#)

FUTURE DECONTAMINANT FOR THE DECONTAMINATION FAMILY OF SYSTEMS (DFOS) PROGRAM OFFICE

US Army Materiel Command Solicitation Number: W911QY08FDECN

August 7, 2008

"The DoD Joint Project Manager for Decontamination (JPM-Decon) is conducting a market survey to identify chemical and biological decontaminants that meet the U.S. Army Center for Health Promotion and Preventive Medicine (USACHPPM) civilian related chemical warfare agent exposure levels for chemical and biological defense. The JPM-Decon (Decontamination Family of Systems (DFoS) Program Office) requests information on decontaminants with chemical and biological efficacy (may be addressed by separate products) comparable or superior to current decontaminants (i.e. HTH, STB, DF-200), have a reduced logistical burden, and compatibility with current applicator systems (i.e. JSTDS-SS) and common military materials (i.e. CARC, metals, plastic, and rubber). DFoS is interested in decontaminants that are currently available for delivery.

Proposed decontaminants will be compared against the following criteria:

- * Chemical Efficacy: GD, HD, VX 99% reduction within 30 minutes
- * Biological efficacy following 30 minute decontaminant exposure:
 - o Biological Endospore and Vegetative Bacteria - No Colony Forming Units (CFU)
 - o Viruses - No Plaque Forming Units (PFU)"

The full article can be found at: https://www.fbo.gov/index?s=opportunity&mode=form&id=f4c38d3f7c42a33ba965a46b47b5245b&tab=core&_cview=0&cck=1&au=&ck=

[Return to Top](#)

AMTRAK ORDERS ADDITIONAL PORTABLE SABRE 4000 ADVANCED DETECTION SYSTEMS

ASIATravelTips.com

August 7, 2008

"Amtrak has purchased additional SABRE 4000 advanced explosives detection systems from Smiths Detection to expand its capability for rapid, non-intrusive screening of passengers, trains and stations.

Using proven Ion Mobility Spectrometry (IMS), the versatile hand-held system can quickly detect and identify explosives as well as narcotics, chemical warfare agents and toxic industrial chemicals. However, it is believed that Amtrak will continue to use only the explosives detection capabilities."

The full article can be found at: <http://www.asiatraveltips.com/news08/78-Security.shtml>

[Return to Top](#)

Chem-Demil News

MILESTONES IN U.S. CHEMICAL WEAPONS STORAGE AND DESTRUCTION

US Army Chemical Materials Agency Fact Sheet

2008

This US Army Chemical Materials Agency fact sheet provides an overview of the US CW storage and destruction programs after 1969.

The full article can be found at: <http://www.cma.army.mil/fndocumentviewer.aspx?docid=003676918>

[Return to Top](#)

MISSION AREA OVERVIEW: PROJECT MANAGER – CHEMICAL STOCKPILE ELIMINATION

US Army Chemical Materials Agency Fact Sheet

2008

This US Army Chemical Materials Agency factsheet provides an overview of the chemical stockpile elimination program.

The full article can be found at: <http://www.cma.army.mil/fndocumentviewer.aspx?docid=003672435>

[Return to Top](#)

END of CB Daily Report.

Send subscription requests, unsubscribing requests, questions and comments to:

Sandy Banks: Sandra.Banks@anser.org

Steve Tesko: Steve.Tesko@anser.org

Heather Williams: Heather.Williams@anser.org

Suzanne Martinez: Suzanne.Martinez@anser.org

Copyright 2008. *Analytic Services Inc.*

[Analytic Services Inc. DMCA Copyright Notice: http://www.homelandsecurity.org/bulletin/Draft_ANSER_DCMA_Copyright_Notice.htm](http://www.homelandsecurity.org/bulletin/Draft_ANSER_DCMA_Copyright_Notice.htm)

Use of these news articles does not reflect official endorsement.

In accordance with Title 17 (USC), Section 107, this material is distributed without profit or payment and is intended for nonprofit research and educational purposes only.

Reproduction for private use or gain is subject to original copyright restrictions.

PRIVACY POLICY

Content provided in the *CB Daily Report* does not reflect the viewpoint(s) of Analytic Services Inc. Analytic Services Inc. does not share, publish, or in any way redistribute subscriber email addresses or any other personal information.